BioSpace News Archive

Secarna Pharmaceuticals GmbH & Co. KG announced the publication of striking new preclinical data demonstrating that bimodal ASOs can enable efficacious long-term antitumor immunity in tumor models compared to current immune checkpoint inhibitors.

Option Care Health, Inc. filed with the U.S. Securities and Exchange Commission a registration statement on Form S-4 containing a joint proxy statement/prospectus in connection with its proposed merger with Amedisys, Inc.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from an interim analysis of Cohort 1 of the Phase 3 THOR study.

BIOLASE, Inc., a global leader in dental lasers, announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly-designated Series I Preferred Stock, par value $0.001 per share, for each outstanding share of BIOLASE common stock held of record as of 5:00 p.m. Eastern Time on June 16, 2023.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) announced the preliminary data of IBI351 (GFH925, KRASG12C inhibitor) is presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Telix Pharmaceuticals Limited advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare Conference being held in New York from June 7 to June 9, 2023.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) and IASO Biotechnology (“IASO Bio”) today jointly announced that the updated data from Phase 1b/2 study of Equecabtagene Autoleucel (Innovent R&D code: IBI326, IASO Bio R&D code: CT103A) was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2-6, 2023.

Ascentage Pharma announced that it has released preliminary results from a Phase Ib/II study of the Bcl-2 inhibitor, lisaftoclax, as a monotherapy or combined with ibrutinib or rituximab in patients with Waldenström macroglobulinemia, in a Poster Presentation at the 59th American Society of Clinical Oncology Annual Meeting that marked the first data readout from a multicenter global study of lisaftoclax in WM.

Cerus Corporation (Nasdaq: CERS) today announced that it has been awarded an additional $8.7 million contract amendment to the original $9.1 million contract by the U.S. Department of Defense (DoD) Industrial Base Analysis and Sustainment (IBAS) program for the development of pathogen.

FogPharma today announced the first patient has been dosed in a first-in-human Phase 1/2 clinical trial of, FOG-001, the company’s first-in-class TCF-blocking β-catenin inhibitor.